Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Voyager Therapeutics, Inc.VYGR · Entity 6271 | Principal Accounting Officer | May 08, 2026 | May 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Voyager Therapeutics, Inc.
Report date May 08, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,749 |
Reported balance
Holding disclosure · report date 2026-05-08 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 36,749 F1: Includes shares of common stock issuable under restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "2015 Plan") and the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan (the "2025 Plan") that vest periodically. Each RSU represents the right to receive one share of common stock upon vesting. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.28 · Expires 2035-01-13 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-05-08 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: This stock option was issued pursuant to the 2015 Plan. The vesting commencement date of the option is the grant date, January 13, 2025. The option vests over four years, with 1/4th of the shares of common stock underlying the option vesting on the one-year anniversary of the vesting commencement date, and an additional 1/36th of the shares of common stock underlying the option vesting monthly thereafter, subject to the Reporting Person's continued service. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.68 · Expires 2036-02-06 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-05-08 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F3: This stock option was issued pursuant to the 2025 Plan. The vesting commencement date of the option is the grant date, February 06, 2026. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting on the first month anniversary of the vesting commencement date, and an additional 1/48th of shares underlying the option vesting monthly thereafter, subject to the Reporting Person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes shares of common stock issuable under restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "2015 Plan") and the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan (the "2025 Plan") that vest periodically. Each RSU represents the right to receive one share of common stock upon vesting.
F2: This stock option was issued pursuant to the 2015 Plan. The vesting commencement date of the option is the grant date, January 13, 2025. The option vests over four years, with 1/4th of the shares of common stock underlying the option vesting on the one-year anniversary of the vesting commencement date, and an additional 1/36th of the shares of common stock underlying the option vesting monthly thereafter, subject to the Reporting Person's continued service.
F3: This stock option was issued pursuant to the 2025 Plan. The vesting commencement date of the option is the grant date, February 06, 2026. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting on the first month anniversary of the vesting commencement date, and an additional 1/48th of shares underlying the option vesting monthly thereafter, subject to the Reporting Person's continued service.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Vor Biopharma Inc.
Report date November 06, 2024 · Filed November 08, 2024
Section 16 reporting ended · disclosed 2024-11-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 50,312 |
Reported balance
After 2024-11-06 transaction · row 1
1 source rowRow 1 · 2024-11-06 · Tax withholding · Disposed 206 · Balance 50,312 F1: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 06, 2024 Filed Nov 8, 2024 16:15 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Tax withholdingCommon Stock | 206 | $0.86 | $177.16 |
DisclosureSEC source: 0001415889-24-026432 · form4-11082024_041112.xml · nonDerivative · entry 1 Quinlan Amy · CIK 0002027706 · Vice President of Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,312 F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 16:15 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Tax withholdingCommon Stock | 343 | $0.80 | $274.40 |
DisclosureSEC source: 0001415889-24-026134 · form4-11052024_041123.xml · nonDerivative · entry 1 Quinlan Amy · CIK 0002027706 · Vice President of Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,518 F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units. Read SEC document |
| September 03, 2024 Filed Sep 4, 2024 16:15 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Tax withholdingCommon Stock | 4,402 | $0.83 | $3,653.66 |
DisclosureSEC source: 0001415889-24-022767 · form4-09042024_040911.xml · nonDerivative · entry 3 Quinlan Amy · CIK 0002027706 · Vice President of Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,861 F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units. Read SEC document |
| August 06, 2024 Filed Sep 4, 2024 16:15 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Tax withholdingCommon Stock | 206 | $0.87 | $179.22 |
DisclosureSEC source: 0001415889-24-022767 · form4-09042024_040911.xml · nonDerivative · entry 2 Quinlan Amy · CIK 0002027706 · Vice President of Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,263 F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units. Read SEC document |
| August 01, 2024 Filed Sep 4, 2024 16:15 UTC | Vor Biopharma Inc. VOR · Entity 4763 | Tax withholdingCommon Stock | 343 | $0.94 | $322.42 |
DisclosureSEC source: 0001415889-24-022767 · form4-09042024_040911.xml · nonDerivative · entry 1 Quinlan Amy · CIK 0002027706 · Vice President of Finance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,469 F1 · shares: Shares were withheld to satisfy the Reporting Person's tax withholding obligations in connection with the settlement of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.